Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis

@article{Lim2007ToxicityAO,
  title={Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis},
  author={Sherry J. Lim and Janice N. Cormier and Barry Feig and Paul F. Mansfield and Robert S Benjamin and Janet R. Griffin and Judy L. Chase and Peter W. T. Pisters and Raphael E Pollock and Kelly K. Hunt},
  journal={Annals of Surgical Oncology},
  year={2007},
  volume={14},
  pages={2309-2318}
}
Treatment of peritoneal recurrence following surgical resection of intra-abdominal sarcomas presents a significant challenge to clinicians. Historically, treatment with systemic chemotherapy has been ineffective and surgical resection alone has not been durable. We prospectively evaluated the feasibility of cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin (CDDP) alone or in combination with mitoxantrone (MITOX) for the treatment of sarcomatosis… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

The New England journal of medicine • 2006
View 3 Excerpts

Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis

S Bonvalot, A Cavalcanti, C Le Pechoux
Eur J Surg Oncol • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…